Otsuka ICU Medical invests US$500M to expand Texas IV manufacturing as demand for resilient supply grows

USA—Otsuka ICU Medical will invest more than US$500 million to expand its intravenous (IV) solutions manufacturing network in the United States, strengthening domestic production and improving long-term supply chain resilience.

The announcement marks the company’s first major expansion since its formation in May 2025 through a joint venture between Otsuka Pharmaceutical Factory America and ICU Medical.

The investment will fund the construction of a new 500,000-square-foot manufacturing facility, along with extensive upgrades to the company’s existing 700,000-square-foot plant in Austin, Texas.

Construction is expected to begin later this year, significantly increasing the site’s production capacity.

According to the company, the expanded campus will support the production of IV solutions for North American healthcare providers while introducing new manufacturing technologies and non-DEHP product innovations.

It also plans to strengthen regulatory readiness by seeking US Food and Drug Administration (FDA) approval for selected Otsuka manufacturing facilities outside the US to supplement regional supply when needed.

Supply disruptions exposed market vulnerabilities

The investment follows major disruptions that affected the US IV fluids market after Hurricane Helene damaged Baxter’s manufacturing facility in North Carolina in September 2024.

The incident significantly reduced national supplies of IV bags and fluids, creating shortages across hospitals and healthcare systems.

Baxter manufactures about 60% of the US IV fluid supply. By November 2024, nearly 86% of healthcare providers had reported shortages of IV-related products, highlighting the risks of relying on a small number of manufacturing sites.

Otsuka ICU Medical said the experience reinforced the need for a more resilient and geographically diversified manufacturing network capable of maintaining supply during emergencies.

Yoshifumi Fujimoto, Chief Executive Officer of Otsuka ICU Medical, said the investment reflects the company’s long-term commitment to a critical area of healthcare.

“By strengthening our US manufacturing footprint and introducing innovation, we are enhancing supply reliability for North American customers while positioning ourselves to better support future regulatory and legislative requirements,” he said.

Expansion aligns with broader US manufacturing trend

The announcement comes as life sciences companies continue to increase manufacturing investments across the US amid policies encouraging domestic production.

Although pharmaceutical manufacturers have led this trend, medical technology companies are also expanding local operations to strengthen supply chains and reduce dependence on overseas production.

In a similar move, Johnson & Johnson recently announced a US$1 billion investment to expand its vision manufacturing operations in Florida as part of a broader US$55 billion commitment to increase its US manufacturing footprint by 2029.

Separately, Otsuka has continued to advance its broader healthcare portfolio.

Earlier this month, the company reported positive Phase III results for its investigational kidney disease therapy, sibeprenlimab, demonstrating continued progress across both its pharmaceutical and manufacturing businesses.